Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics, and Gynecological Oncology, Poznan University of Medical Sciences, 60-535 Poznan, Poland.
J Clin Endocrinol Metab. 2011 Nov;96(11):3493-501. doi: 10.1210/jc.2011-0501. Epub 2011 Aug 24.
A randomized trial on women with polycystic ovary syndrome (PCOS) compared simvastatin, metformin, and a combination of these drugs.
The aim of the study was to evaluate long-term effects of simvastatin and metformin on PCOS.
Women with PCOS (n = 139) were randomized to simvastatin (S), metformin (M), or simvastatin plus metformin (SM) groups. Evaluations were performed at baseline and at 3 and 6 months.
The study was conducted at a university medical center.
We measured the change of serum total testosterone.
Ninety-seven subjects completed the study. Total testosterone decreased significantly and comparably in all groups: by 25.6, 25.6, and 20.1% in the S, M, and SM groups, respectively. Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Dehydroepiandrosterone sulfate declined significantly only in the S group. Total cholesterol and low-density lipoprotein cholesterol significantly declined only in the S and SM groups. Ongoing reduction of ovarian volume, decreased hirsutism, acne and testosterone were observed between 0 and 3 months as well as between 3 and 6 months. Improvement of lipid profile, C-reactive protein, and soluble vascular cell adhesion molecule-1 occurred only during the first 3 months of treatment, with little change thereafter. Treatments were well tolerated, and no significant adverse effects were encountered.
Long-term treatment with simvastatin was superior to metformin. Improvement of ovarian hyperandrogenism continued throughout the duration of the study.
一项针对多囊卵巢综合征（PCOS）女性的随机试验比较了辛伐他汀、二甲双胍和这两种药物的联合应用。
本研究旨在评估辛伐他汀和二甲双胍对 PCOS 的长期影响。
将 139 名 PCOS 女性随机分为辛伐他汀（S）、二甲双胍（M）或辛伐他汀加二甲双胍（SM）组。在基线和 3 个月、6 个月时进行评估。
本研究在一所大学医学中心进行。
我们测量了血清总睾酮的变化。
97 名受试者完成了研究。所有组的总睾酮均显著且相当降低：S、M 和 SM 组分别降低了 25.6%、25.6%和 20.1%。辛伐他汀和二甲双胍均可改善月经周期，并降低多毛症、痤疮、卵巢体积、体重指数、C 反应蛋白和可溶性血管细胞黏附分子-1。仅在 S 组中脱氢表雄酮硫酸酯显著下降。仅 S 和 SM 组的总胆固醇和低密度脂蛋白胆固醇显著下降。在 0 至 3 个月和 3 至 6 个月期间，卵巢体积持续缩小，多毛症、痤疮和睾酮减少。仅在治疗的前 3 个月内观察到血脂谱、C 反应蛋白和可溶性血管细胞黏附分子-1的改善，此后变化不大。治疗耐受良好，未发现明显不良反应。
长期使用辛伐他汀优于二甲双胍。卵巢高雄激素血症的改善持续整个研究期间。
